Tumors in Pigmented Skin

  • Chalid AssafEmail author
  • Alice U. Amani
  • Egemen Yildiz
  • Sam T. Hwang


Skin cancer is worldwide the most common malignancy; non-melanoma skin cancer and malignant melanoma together represent 40% of all neoplasms in white Caucasians [1]. The worldwide incidence for basal cell carcinoma varies widely with highest rates in Australia >1000/100,000/person-year and lowest in parts of Africa <1/100,000/person-year. In the UK the average incidence rates were 76/100,000/person-year and 22/100,000 person-year for basal cell and squamous cell carcinoma, respectively [2]. In individuals with pigmented ethnic skin, the incidence of skin cancer is clearly lower as compared with white-skinned individuals, possibly as a result of the photoprotective effects of melanin [3], but skin cancer is often associated with greater mortality and morbidity in pigmented skin. This may be associated either with late diagnosis of the neoplasms in an advanced stage or with different tumor characteristics in populations with pigmented ethnic skin. It is important to further assess any differences of skin cancer between Caucasian and non-Caucasian populations and evaluate the etiology and risk factors in skin of color for developing cancer.


  1. 1.
    Ridky TW. Nonmelanoma skin cancer. J Am Acad Dermatol. 2007;57:484–501.CrossRefPubMedGoogle Scholar
  2. 2.
    Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of non melanoma skin cancer. Br J Dermatol. 2012;166:1069–80.CrossRefPubMedGoogle Scholar
  3. 3.
    Brenner M, Hearing VJ. The protective role of melanin against UV damage in human skin. Photochem Photobiol. 2008;84:539–49.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Rubin A, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med. 2005;353:2262–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Gloster HM, Neal K. Skin cancer in skin of color. J Am Acad Dermatol. 2006;55:741–60.CrossRefPubMedGoogle Scholar
  6. 6.
    Byrd-Miles K, Toombs EL, Peck GL. Skin cancer in individuals of African, Asian, Latin American, and American-Indian descent: differences in incidence, clinical presentation, and survival compared to Caucasians. J Drugs Dermatol. 2007;6:10–6.PubMedGoogle Scholar
  7. 7.
    Rogers HW, Weinstok MA, Feldman SR, et al. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012. JAMA Dermatol. 2015;151:1081–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Asgari MM, Moffet HH, Ray GT, et al. Trends in basal cell carcinoma incidence and identification of high-risk subgroups, 1998-2012. JAMA Dermatol. 2015;151:976–81.CrossRefPubMedGoogle Scholar
  9. 9.
    Gallagher RP, Hill GB, Bajdik CD, et al. Sunlight exposure, pigmentary factors, and risk of non melanocytic skin cancer. I. Basal cell carcinoma. Arch Dermatol. 1995;131:157–63.CrossRefPubMedGoogle Scholar
  10. 10.
    Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B. 2001;63:8–18.CrossRefPubMedGoogle Scholar
  11. 11.
    Lear JT, Tan BB, Smith AG, et al. Risk factors for basal cell carcinoma in the UK: case-control study in 806 patients. J R Soc Med. 1997;90:371–4.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Agbai ON, Buster K, Sanchez M, et al. Skin cancer and photoprotection in people of color: a review and recommendations for physicians and the public. J Am Acad Dermatol. 2014;70:748–62.CrossRefPubMedGoogle Scholar
  13. 13.
    Halder RM, Bridgeman-Shah S. Skin cancer in African Americans. Cancer. 1995;75(suppl):667–73.CrossRefPubMedGoogle Scholar
  14. 14.
    Kundu RV, Patterson S. Dermatologic conditions in skin of color: part I. Special considerations for common skin disorders. Am Fam Physician. 2013;87:850–6.PubMedGoogle Scholar
  15. 15.
    Kimonis VE, Goldstein AM, Pastakia B, et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet. 1997;69:299–308.CrossRefPubMedGoogle Scholar
  16. 16.
    Kulkarni P, Brashear R, Chuang TY. Nevoid basal cell carcinoma syndrome in a person with dark skin. J Am Acad Dermatol. 2003;49:332–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Halpern AC, Kopp LP. Awareness, knowledge and attitudes to non-melanoma skin cancer and actinic keratosis among the general public. Int J Dermatol. 2005;44:107–11.CrossRefPubMedGoogle Scholar
  18. 18.
    Montague M, Borland MR, Sinclair C. Slip! Slop! Slap! And SunSmart, 1980-2000: skin cancer control and 20 years of population-based campaigning. Health Educ Behav. 2001;28:290–305.CrossRefPubMedGoogle Scholar
  19. 19.
    Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol. 2009;27:3–9.CrossRefPubMedGoogle Scholar
  20. 20.
    SEER*Explorer: An interactive website for SEER cancer statistics [Internet]. Beta Version. Surveillance Research Program, National Cancer Institute. Available from
  21. 21.
    Hu S, Parmet Y, Allen G, et al. Disparity in melanoma: a trend analysis of melanoma incidence and stage at diagnosis among whites, Hispanics, and blacks in Florida. Arch Dermatol. 2009;145:1369–74.PubMedGoogle Scholar
  22. 22.
    Rouhani P, Hu S, Kirsner RS. Melanoma in Hispanic and black Americans. Cancer Control. 2008;15:248–53.CrossRefPubMedGoogle Scholar
  23. 23.
    Clairwood M, Ricketts J, Grant-Kels J, et al. Melanoma in skin of color in Connecticut: an analysis of melanoma incidence and stage at diagnosis in non-Hispanic blacks, non-Hispanic whites, and Hispanics. Int J Dermatol. 2014;53:425–33.CrossRefPubMedGoogle Scholar
  24. 24.
    Watson M, Johnson CJ, Chen VW, et al. Melanoma surveillance in the United States: overview of methods. J Am Acad Dermatol. 2011;65(suppl 1):S6–16.PubMedGoogle Scholar
  25. 25.
    Cartee TV, Kini SP, .Chen SC: Melanoma reporting to central cancer registries by US dermatologists: an analysis of the persistent knowledge and practice gap. J Am Acad Dermatol, 2011; 65(suppl 1): S124–S325.PubMedGoogle Scholar
  26. 26.
    Hu S, Soza-Vento RM, Parker DF, et al. Comparison of stage at diagnosis of melanoma among Hispanic, black, and white patients in Miami-Dade County. Florida Arch Dermatol. 2006;142:704–8.PubMedGoogle Scholar
  27. 27.
    Cockburn MG, Zadnick J, Deapen D. Developing epidemic of melanoma in the Hispanic population of California. Cancer. 2006;106:1162–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Tucker MA, Goldstein AM. Melanoma etiology: where are we? Oncogene. 2003;22:3042–52.CrossRefPubMedGoogle Scholar
  29. 29.
    Park SL, Le Marchand L, Wilkens LR, et al. Risk factors for malignant melanoma in white and non-white/non-African American populations: the multiethnic cohort. Cancer Prev Res (Phila). 2012;5:423–34.CrossRefGoogle Scholar
  30. 30.
    Eide MJ, Weinstock MA. Association of UV index, latitude, and melanoma incidence in nonwhite populations-US surveillance, epidemiology, and end results (SEER) program, 1992 to 2001. Arch Dermatol. 2005;141:477–81.CrossRefPubMedGoogle Scholar
  31. 31.
    Hu S, Ma F, Collado-Mesa F, et al. UV radiation, latitude, and melanoma in US Hispanics and blacks. Arch Dermatol. 2004;140:819–24.CrossRefPubMedGoogle Scholar
  32. 32.
    Tadokoro T, Kobayashi N, Zmudzka BZ, et al. UV-induced DNA damage and melanin content in human skin differing in racial/ethnic origin. FASEB J. 2003;17:1177–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Akslen LA, Puntervoll H, Bachmann IM, et al. Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma Res. 2008;18:29–35.CrossRefPubMedGoogle Scholar
  34. 34.
    Saldanha G, Potter L, Daforno P, et al. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies. Clin Cancer Res. 2006;12:4499–505.CrossRefPubMedGoogle Scholar
  35. 35.
    Ibrahim ZA, Narihan MZ, Ojep DN, et al. Cyclin D1 expression in acral melanoma: a case control study in Sarawak. Malays J Pathol. 2012;34:89–95.PubMedGoogle Scholar
  36. 36.
    Pasquali E, García-Borrón JC, Fargnoli MC, et al. MC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented Caucasians: a pooled-analysis from the M-SKIP project. Int J Cancer. 2015;136:618–31.PubMedGoogle Scholar
  37. 37.
    Lu J, Dai B, Kong Y, et al. Acral melanoma in Chinese: a clinicopathological and prognostic study of 142 cases. Sci Rep. 2016;6(31432)Google Scholar
  38. 38.
    Bradford PT, Goldstein MA, Master ML, et al. Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005. Arch Dermatol. 2009;145:427–34.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Soon SL, Solomon AR Jr, Papadopoulos D, et al. Acral lentiginous melanoma mimicking benign disease: the Emory experience. J Am Acad Dermatol. 2003;48:183–8.CrossRefPubMedGoogle Scholar
  40. 40.
    Lino-Silva LS, Domínguez-Rodríguez JA, Aguilar-Romero JM, et al. Melanoma in Mexico: clinicopathologic features in a population with predominance of acral lentiginous subtype. Ann Surg Oncol. 2016;23:4189–94.CrossRefPubMedGoogle Scholar
  41. 41.
    Seleye-Fubara D, Etebu EN. Histological review of melanocarcinoma in Port Harcourt. Niger J Clin Pract. 2005;8:110–3.PubMedGoogle Scholar
  42. 42.
    Lodder JV, Simson W, Becker PJ. Malignant melanoma of the skin in black south Africans: a 15-year experience. S Afr J Surg. 2010;3:76–9.Google Scholar
  43. 43.
    Phan A, Touzet S, Dalle S, et al. Acral lentiginous melanoma: a clinicoprognostic study of 126 cases. Br J Dermatol. 2006;155:561–9.CrossRefPubMedGoogle Scholar
  44. 44.
    Zebary A, Omholt K, Vassilaki I, et al. KIT, NRAS, BRAF and PTEN mutations in a Swedish sample with acral lentiginous melanoma. J Dermatol Sci. 2013;72:284–9.CrossRefPubMedGoogle Scholar
  45. 45.
    Namiki T, Coelho SG, Hearing VJ. NUAK2: an emerging acral melanoma oncogene. Oncotarget. 2011;2:695–704.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Haigh P, DiFronzo L, McCready D. Optimal excision margins for primary cutaneous melanoma: a systematic review and meta-analysis. Can J Surg. 2003;46:419–26.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Agarwala SS. Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther. 2009;9:587–95.CrossRefPubMedGoogle Scholar
  48. 48.
    Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768–85.CrossRefPubMedGoogle Scholar
  49. 49.
    Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States 1973-2002. Arch Dermatol. 2007;143:854–9.CrossRefPubMedGoogle Scholar
  50. 50.
    Weinstock MA, Gardstein B. Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality. Am J Public Health. 1999;89:1240.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Weinstock MA, Reynes JF. The changing survival of patients with mycosis fungoides: a population-based assessment of trends in the United States. Cancer. 1999;85:208–12.CrossRefPubMedGoogle Scholar
  52. 52.
    Kim EJ, Hess S, Richardson SK, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest. 2005;115:798–812.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Litvinov IV, Shtreis A, Kobayashi K, et al. Investigating potential exogenous tumor initiating and promoting factors for cutaneous T-cell lymphomas (CTCL), a rare skin malignancy. Oncoimmunology. 2016;5:e1175799.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Hwang ST, Janik JE, Jaffe ES, et al. Mycosis fungoides and Sézary syndrome. Lancet. 2008(9616); 371:945–57.Google Scholar
  55. 55.
    Vonderheid EC, Bernengo MG, Burg G, et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol. 2002;46:95–106.CrossRefPubMedGoogle Scholar
  56. 56.
    Akaraphanth R, Douglass MC, Lim HW. Hypopigmented mycosis fungoides: treatment and a 6.5-year follow-up of 9 patients. J Am Acad Dermatol. 2000;42:33–9.CrossRefPubMedGoogle Scholar
  57. 57.
    Möbs M, Knott M, Fritzen B, et al. Diagnostic tools in Sezary syndrome. G Ital Dermatol Venereol. 2010;145:385–91.PubMedGoogle Scholar
  58. 58.
    Macaulay WL. Lymphomatoid papulosis. A continuing self-healing eruption, clinically benign - histologically malignant. Arch Dermatol. 1968;97:23–30.CrossRefPubMedGoogle Scholar
  59. 59.
    Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch cutaneous lymphoma group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95:3653–61.PubMedGoogle Scholar
  60. 60.
    Wilcox RA. Cutaneous B-cell lymphomas: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91:1052–5.CrossRefPubMedGoogle Scholar
  61. 61.
    Assaf C, Hummel M, Steinhoff M, et al. Early TCR-beta and TCR-gamma PCR detection of T-cell clonality indicates minimal tumor disease in lymph nodes of cutaneous T-cell lymphoma: diagnostic and prognostic implications. Blood. 2005;105:503–10.CrossRefPubMedGoogle Scholar
  62. 62.
    Möbs M, Cerroni L, Flaig MJ, et al. Molecular diagnostics in cutaneous lymphomas. J Dtsch Dermatol Ges. 2013;11(suppl 4):25–35.CrossRefPubMedGoogle Scholar
  63. 63.
    Trautinger F, Eder J, Assaf C, et al. European organisation for research and treatment of Cancer Consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - update 2017. Eur J Cancer. 2017;77:57–74.CrossRefPubMedGoogle Scholar
  64. 64.
    Newman PL, Fletcher CD. Smooth muscle tumours of the external genitalia: clinicopathological analysis of a series. Histopathology. 1991;18:523–9.CrossRefPubMedGoogle Scholar
  65. 65.
    Smit DL, Mensenkamp AR, Badeloe S. Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germline mutation analysis. Clin Genet. 2011;79:49–59.CrossRefPubMedGoogle Scholar
  66. 66.
    Badeloe S, van Geel M, van Steensel MA, et al. From gene to disease; cutaneous leiomyomatosis. Ned Tijdschr Geneeskd. 2007;151:300–4.PubMedGoogle Scholar
  67. 67.
    Fletcher CDM. Soft tissue tumors. In: Fletcher CDM, editor. Diagnostic histopathology of tumors. 3rd ed. Philadelphia: Churchill Livingstone; 2007. p. 1527–93.Google Scholar
  68. 68.
    Badeloe S, Frank J. Clinical and molecular genetic aspects of hereditary multiple cutaneous leiomyomatosis. Eur J Dermatol. 2009;19:545–51.PubMedGoogle Scholar
  69. 69.
    Raj S, Calonje E, Kraus M, et al. Cutaneous pilar leiomyoma: clinicopathologic analysis of 53 lesions in 45 patients. Am J Dermatopathol. 1997;19:2–9.CrossRefPubMedGoogle Scholar
  70. 70.
    Malhotra P, Walia H, Singh A, et al. Leiomyoma cutis: a clinopathological series of 37 cases. Indian J Dermatol. 2010;55:337–41.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Rongioletti F, Fausti V, Ferrando B, et al. A novel missense mutation in fumarate hydratase in an Italian patient with a diffuse variant of cutaneous leiomyomatosis (Reed’s syndrome). Dermatology. 2010;221:378–80.CrossRefPubMedGoogle Scholar
  72. 72.
    Thompson JA Jr. Therapy for painful cutaneous leiomyomas. J Am Acad Dermatol. 1985;13:865–7.CrossRefPubMedGoogle Scholar
  73. 73.
    Christenson LJ, Smith K, Arpey CJ. Treatment of multiple cutaneous leiomyomas with CO2 laser ablation. Dermatol Surg. 2000;26:319–22.CrossRefPubMedGoogle Scholar
  74. 74.
    Kim G. Multiple cutaneous and uterine leiomyomatosis (Reed's syndrome). Dermatol Online J. 2005;11:21.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Chalid Assaf
    • 1
    Email author
  • Alice U. Amani
    • 2
  • Egemen Yildiz
    • 3
    • 4
  • Sam T. Hwang
    • 5
  1. 1.Department of Dermatology and VenerologyHELIOS Klinikum KrefeldKrefeldGermany
  2. 2.Service de DermatologieCentre Hospitalier UniversitaireKigaliRwanda
  3. 3.Department of DermatologyUniversity of California, Davis School of MedicineSacramentoUSA
  4. 4.Faculty of MedicineHacettepe UniversityAnkaraTurkey
  5. 5.Department of DermatologyUniversity of California, Davis School of MedicineSacramentoUSA

Personalised recommendations